159 related articles for article (PubMed ID: 31305194)
1. Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma.
Watanabe J; Natsumeda M; Kanemaru Y; Okada M; Oishi M; Kakita A; Fujii Y
Leuk Lymphoma; 2019 Dec; 60(14):3587-3589. PubMed ID: 31305194
[No Abstract] [Full Text] [Related]
2. Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis.
Rimelen V; Ahle G; Pencreach E; Zinniger N; Debliquis A; Zalmaï L; Harzallah I; Hurstel R; Alamome I; Lamy F; Voirin J; Drénou B
Acta Neuropathol Commun; 2019 Mar; 7(1):43. PubMed ID: 30885253
[No Abstract] [Full Text] [Related]
3. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor DNA profiling for childhood brain tumors: Technical challenges and evidence for utility.
Liu AP; Northcott PA; Robinson GW; Gajjar A
Lab Invest; 2022 Feb; 102(2):134-142. PubMed ID: 34934181
[TBL] [Abstract][Full Text] [Related]
5. Flowcytometric evaluation of cerebrospinal fluid in childhood ALL identifies CNS involvement better then conventional cytomorphology.
de Haas V; Pieters R; van der Sluijs-Gelling AJ; Zwaan CM; de Groot-Kruseman HA; Sonneveld E; Stigter RL; van der Velden VHJ
Leukemia; 2021 Jun; 35(6):1773-1776. PubMed ID: 32855440
[No Abstract] [Full Text] [Related]
6. Establishing a prognostic score for primary CNS lymphomas.
Ferreri AJ; Reni M
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):303-4; author reply 304-5. PubMed ID: 15629627
[No Abstract] [Full Text] [Related]
7. Circulating tumour DNA, microRNA and metabolites in cerebrospinal fluid as biomarkers for central nervous system malignancies.
Zorofchian S; Iqbal F; Rao M; Aung PP; Esquenazi Y; Ballester LY
J Clin Pathol; 2019 Apr; 72(4):271-280. PubMed ID: 30467241
[TBL] [Abstract][Full Text] [Related]
8. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma.
Rubenstein JL; Wong VS; Kadoch C; Gao HX; Barajas R; Chen L; Josephson SA; Scott B; Douglas V; Maiti M; Kaplan LD; Treseler PA; Cha S; Hwang JH; Cinque P; Cyster JG; Lowell C
Blood; 2013 Jun; 121(23):4740-8. PubMed ID: 23570798
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).
Sasayama T; Nakamizo S; Nishihara M; Kawamura A; Tanaka H; Mizukawa K; Miyake S; Taniguchi M; Hosoda K; Kohmura E
Neuro Oncol; 2012 Mar; 14(3):368-80. PubMed ID: 22156547
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid interleukin-10 levels in primary central nervous system lymphoma: a possible marker of response to treatment?
Salmaggi A; Eoli M; Corsini E; Gelati M; Frigerio S; Silvani A; Boiardi A
Ann Neurol; 2000 Jan; 47(1):137-8. PubMed ID: 10632117
[No Abstract] [Full Text] [Related]
11. MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma.
Hiemcke-Jiwa LS; Leguit RJ; Snijders TJ; Bromberg JEC; Nierkens S; Jiwa NM; Minnema MC; Huibers MMH
Br J Haematol; 2019 Jun; 185(5):974-977. PubMed ID: 30408153
[No Abstract] [Full Text] [Related]
12. Marker (+) CNS germ cell tumors in remission: are surveillance MRI scans necessary?
Martinez S; Khakoo Y; Gilheeney S; Kramer K; Wolden S; Souweidane M; Dunkel IJ
Pediatr Blood Cancer; 2014 May; 61(5):853-4. PubMed ID: 24375894
[TBL] [Abstract][Full Text] [Related]
13. Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis.
Routman DM; Chera BS; Gupta GP
Cancer J; 2020; 26(2):116-123. PubMed ID: 32205535
[TBL] [Abstract][Full Text] [Related]
14. Multi-marker algorithms based on CXCL13, IL-10, sIL-2 receptor, and β2-microglobulin in cerebrospinal fluid to diagnose CNS lymphoma.
Maeyama M; Sasayama T; Tanaka K; Nakamizo S; Tanaka H; Nishihara M; Fujita Y; Sekiguchi K; Kohta M; Mizukawa K; Hirose T; Itoh T; Kohmura E
Cancer Med; 2020 Jun; 9(12):4114-4125. PubMed ID: 32314548
[TBL] [Abstract][Full Text] [Related]
15. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid beta-2-microglobulin in adult patients with acute leukemia or lymphoma: a useful marker in early diagnosis and monitoring of CNS-involvement.
Hansen PB; Kjeldsen L; Dalhoff K; Olesen B
Acta Neurol Scand; 1992 Mar; 85(3):224-7. PubMed ID: 1575009
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
[TBL] [Abstract][Full Text] [Related]
18. Comparison of circulating DNA from plasma and urine for EGFR mutations in NSCLC patients.
Zhang H; He B; Cui J; Zhao M; Zhang Z
Cancer Biomark; 2018; 23(3):427-436. PubMed ID: 30223392
[TBL] [Abstract][Full Text] [Related]
19. Molecular Monitoring of Cell-Free Circulating Tumor DNA in Non-Hodgkin Lymphoma.
Melani C; Roschewski M
Oncology (Williston Park); 2016 Aug; 30(8):731-8, 744. PubMed ID: 27539624
[TBL] [Abstract][Full Text] [Related]
20. Advances in the management of primary central nervous system lymphoma.
Dunleavy K
Clin Adv Hematol Oncol; 2017 Sep; 15(9):677-679. PubMed ID: 28949937
[No Abstract] [Full Text] [Related]
[Next] [New Search]
